Use of short-acting insulin aspart in managing older people with diabetes by Marouf, Eltayeb & Sinclair, Alan J
© 2009 Marouf and Sinclair, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2009:4 187–190 187
REVIEW
Use of short-acting insulin aspart in managing 
older people with diabetes
Eltayeb Marouf
Alan J Sinclair
Institute of Diabetes for Older 
People – IDOP, Bedfordshire 
and Hertfordshire Postgraduate 
Medical School, University 
of Bedfordshire, UK
Correspondence:   Alan Sinclair
Beds and Herts Postgraduate Medical 
School, Putteridge Bury Campus, Hitchin 
Road, Luton, LU2 8LE, UK
Tel +44 1582 743285
Fax +44 1582 743286
Email alan.sinclair@beds.ac.uk
Abstract: Type 2 diabetes mellitus affects 5.9% of the world adult population, with older people 
and some ethnic groups disproportionately affected. Treatment of older people with diabetes 
differs in many ways from that in younger adults since the majority have type 2 disease and are 
at particular risk of macrovascular rather than disabling microvascular disease. Insulin therapy, 
the most effective of diabetes medications, can reduce any level of elevated HBA1c if used in 
adequate doses. However, some clinicians are often reluctant to initiate insulin therapy in older 
people with diabetes mainly out of their concerns about adverse reactions to insulin, particularly 
hypoglycemia. There is evidence suggesting that insulin aspart appears to act similarly to regular 
human insulin in older people with type 2 diabetes mellitus. Insulin aspart can be used in the 
treatment of older people with diabetes, but this should be individualized. There is evidence that it 
improves postprandial glucose control, improves long-term metabolic control, reduces risk of major 
nocturnal hypoglycemia and increases patient satisfaction compared with soluble insulin.
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Introduction
The global epidemic of type 2 diabetes continues unabated and now affects 5.9% of 
the world’s adult population. Older people and members of some ethnic groups are 
disproportionately affected.1
An age-associated hyperglycemia phase and glucose intolerance in older people 
was ﬁ  rst described in 19212 and has been conﬁ  rmed on many occasions since.3 The 
clinical presentation of diabetes in older people is often non speciﬁ  c and atypical and 
as a result the diagnosis is often missed or delayed. In addition older people with 
diabetes have higher rates of functional, psychological and cognitive impairments, and 
disabilities. Moreover, older people often have a wide co-morbidity proﬁ  le linked to 
the inevitable consumption of multiple medications, and management guidance up to 
now has been relatively limited due to the lack of focused clinical guidelines, despite 
the overwhelming evidence base in diabetes generally.
There are no outcome data on the long term effect of tight glycemic control in older 
people with diabetes, and it is by a process of extrapolation from data on young and middle 
age diabetic subjects that the management of type 2 older people remains essentially the 
same as in younger patients. Modiﬁ  cation of lifestyle and dietary advice plus the targeted 
use of single oral agents such as metformin are the most important early management 
steps. When these measures fail to control the symptoms and improve glycemic 
control then other oral antidiabetic medications and insulin analogs can be considered. 
This paper describes the value of using a speciﬁ  c short-duration insulin analog.
Management of diabetes in older people
The consensus statement from the American Diabetes Association and the 
European Association for the study of Diabetes published in 2006 on the Clinical Interventions in Aging 2009:4 188
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management of hyperglycemia in type 2 diabetes produced 
a consensus algorithm for the initiation and adjustment 
of therapy.4
Treatment of older people with diabetes differs in many 
ways from that in younger adults since the majority have 
type 2 disease and are at particular risk of macrovascular 
rather than disabling microvascular disease. Treatment 
approaches therefore need to take particular account of 
cardiovascular risk factors5 particularly in those at home or 
in care homes.6–7 The decision to offer treatment should be 
based on the likely beneﬁ  t/risk ratio for the intervention in 
the individual concerned, but factors such as vulnerability 
to hypoglycemia, ability to self-manage, the presence or 
absence of other pathologies, the cognitive status, and life 
expectancy must be considered.
Concern about hypoglycemia and lack of evidence of 
beneﬁ  t has contributed to underutilization of insulin in 
older people with type 2 diabetes in the past. Following the 
landmark UKPDS (United Kingdom Prospective Diabetes 
Study) it is clear that many elderly patients treated with diet 
and oral antidiabetic agents will develop beta-cell failure and 
will be at risk of worsening glycemic control with reduced 
well-being unless insulin is considered. The UKPDS8 and 
Kumamoto University studies9 utilized a target HbA1c level 
of 7.0% that may be unrealistic in the context of hypoglyce-
mic risk for many older people. The Steno-2 study,10 which 
includes treatment of macrovascular risk factors as well as 
glycemic control, represents a multifactoral approach to 
managing diabetes that is appropriate for all older people 
in the context of a healthy aging program combining life-
style and therapeutic interventions. Recommendations from 
the European Diabetes Working Party For Older People 
2000–2004 (available at www.eugms.org) suggest aiming 
for a target HbA1c of 6.5% to 7.5% for subjects with single 
system involvement, with the precise target depending on 
existing cardiovascular disease, presence of microvascular 
complications, and ability to self-manage.11
Principles of insulin therapy
in older people
Insulin therapy, the most effective of diabetes medications, 
can reduce any level of elevated HbA1c if used in adequate 
doses. However, some clinicians are often reluctant to initi-
ate insulin therapy in older people with diabetes mainly 
out of their concerns about adverse reactions to insulin, 
particularly hypoglycemia (Table 1). Hypoglycemic risk can 
be minimized by initial careful assessment of the patient’s 
cognitive function, by patient education, and careful selection 
of treatment options and glycemic targets.
Insulin aspart
The human insulin analog, insulin aspart, with its proline 
having been replaced by the negatively charged aspartic acid 
at position 28 of the B-chain, has an insulin-receptor afﬁ  nity 
similar to that of human insulin.12
It has a shorter onset and duration of action and can be 
given immediately before meals.13 Its unique molecular 
structure that its absorption is fast, its action is rapid and that 
its duration of action is short (Figure 1). Other researchers 
suggested that subcutaneous injections of insulin aspart just 
before meals better mimic the endogenous insulin proﬁ  le in 
blood compared with human insulin, resulting in improved 
glucose control in a meal-related insulin regimen.14–16
Home et al17 in a 6-month, prospective, randomized, 
open-label, parallel study, the effect of insulin aspart on long 
term glycemic control was compared with soluble human 
insulin in 1070 patients with type 1 diabetes. The study found 
that after 8 months treatment, HbA1c was signiﬁ  cantly lower 
(by 0.12%) with insulin aspart than soluble human insulin.
Table 1 Concerns about the use of insulin in older people
• Hypoglycemia
•  Inability to do regular blood sugar monitoring
• Cognitive  impairment
• Visual impairment
• Living  alone
• Polypharmacy
•  Effects of comorbidities
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Figure 1 The timing of action for insulin aspart.  A euglycemic clamp is used for delivery 
of the insulin aspart (0.2 units/kg of body weight, delivered into the abdomen).   The 
use of this graph helps patients avoid “insulin stacking”. For example, 3 hours after 
the administration of 10 units of insulin aspart, one can estimate that there is still 
40% times 10 units, or 4 units, of insulin remaining. Reproduced with permission from 
Hirsch IB, Insulin analogues. New Engl J Med. 2005;352:174–183.14 Copyright © 2005 
Massachusetts Medical Society.   All rights reserved.Clinical Interventions in Aging 2009:4 189
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Treatment satisfaction assessed by the WHO DTSQ 
(Diabetes Treatment and Satisfaction Questionnaire) was 
signiﬁ  cantly improved with insulin aspart.16 The relative risk 
of a major hypoglycemic episode with insulin aspart com-
pared with soluble human insulin was 0.83 (0.59–1.18, NS). 
Major night-time hypoglycemic events requiring parenteral 
treatment were less with insulin aspart (1.3 vs 3.4% of 
patients, p  0.05). Other studies have also found that insulin 
aspart is superior to soluble human insulin in controlling 
post-prandial blood sugar.18
A recent evidence-based medicine review of biphasic 
insulin aspart (BIAsp) 30 in type 2 diabetes mellitus has 
concluded that the reported efﬁ  cacy and tolerability of BIAsp 
30 in the treatment of diabetes based on a variety of clinical 
endpoints is supported by a good body of evidence relating 
to its use in different dosage regimens and in comparison 
with other insulin treatment regimens.19 Chlup et al studied 
57 individuals with type 2 diabetes, comparing the use of 
human regular insulin and insulin aspart, and found that 
insulin aspart appears to be more effective than human 
regular insulin.20 Moreover, another short-acting insulin 
(insulin glulisine) was found to provide a small improvement 
in glycemic control compared with regular human insulin 
in patients with type 2 diabetes who are already relatively 
very well controlled in insulin alone or insulin plus oral 
hypoglycemic agents.21
Use of insulin aspart in older people
Studies comparing insulin aspart and regular insulin in 
elderly patients with type 2 diabetes have been conducted 
by Meneilly.22 The aim of the studies was to evaluate the 
pharmacokinetic and pharmacodynamic properties of insulin 
aspart in older people with diabetes. They studied 19 patients 
(10 males and 9 females), age 72 ± 1 years, BMI 27 ± 1 kg/m2 
and HbA1c 6.4 ± 0.1%, diabetes duration 5 years; 9 patients 
were treated with metformin and 10 patients with diet. In a 
random order the subjects underwent 2 studies.
In one study, 0.1 units/kg of regular insulin were admin-
istered at 7:30 AM. Thirty minutes later at time 0 subjects 
were given 235 mL of Ensure Plus Fibre® (Abbott). The other 
study was identical to the ﬁ  rst study except that insulin aspart 
0.1 units/kg was given at time zero. Insulin and glucose val-
ues were measured at regular intervals. The results indicate 
that insulin aspart appears to act similarly to regular human 
insulin in older people with type 2 diabetes (Figure 2).
Warren et al,23 in a multi-center open-label randomized 
cross-over two-arm study of 10 weeks’ treatment, also looked 
at post-prandial versus pre-prandial dosing of BIAsp 30 in 
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Figure 2   Insulin and glucose values during the test meal in response to regular 
insulin and insulin aspart in 19 patients (10 males and 9 females), age 72 ± 1 years, 
BMI 27 ± 1 kg/m2 and HbA1c 6.4 ± 0.1% and diabetes duration 5 years. Reproduced 
with permission from Meneilly GS.   A comparison of insulin aspart and regular insulin 
in elderly patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(5):754–755.22 
Copyright © 2007 Blackwell Publishing.
elderly type 2 diabetes patients. Their conclusion was that 
post-prandial injection of BIAsp 30 may be an acceptable 
alternative to minimize the risk of hypoglycemia for some 
older people with type 2 diabetes (Figure 3).
In a sub-group analysis,24 the efﬁ  cacy, safety and treatment 
satisfaction of insulin aspart was evaluated in elderly patients 
with type 2 diabetes in the PRESENT Korea NovoMix study. 
In this 6-month, prospective study, patients inadequately 
controlled on previous therapies achieved better glycemia 
(reduction of HbA1c of 1.2 ± 1.6%; reductions of fasting 
plasma glucose and post-prandial glucose of 2.3 ± 3.5 mmol/L 
and 4.8 ± 5.3 mmol/L at 6 months, respectively, p  0.0001 
for all). Hypoglycemia rates were lower and weight gain was 
minimal. Treatment satisfaction was greater than 80%.
Miyashita et al conducted a prospective, randomized study 
for optimal insulin therapy in type 2 diabetic patients with 
secondary failure and found that both basal-bolus therapy with 
the ultra rapid-acting insulin analog and conventional therapy 
with the twice daily BIAsp produce comparable reduction in 
HbA1c in type 2 diabetic patients with secondary failure.25 
With particular reference to elderly and given that their appe-
tite may be unstable, it may be preferable to treat them with 
a fast-acting insulin eg, insulin aspart, the dose of which is 
dependable on the actual amount of food consumed.Clinical Interventions in Aging 2009:4 190
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With this increasing evidence base, the European 
Commission announced in September, 2007, their approval 
of rapidly acting insulin aspart (NovoRapid®; Novo Norkisk) 
in the treatment of diabetes in elderly patients.
Conclusion
Insulin aspart can be used in the treatment of older people with 
diabetes; however this treatment should be individualized. 
There is evidence that it improves post-prandial glucose 
control, improves long-term metabolic control, reduces 
risk of major nocturnal hypoglycemia and increases patient 
satisfaction compared with soluble insulin.
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Figure 3 Glycemic proﬁ  les at the end of each treatment period. Ninety-three elderly 
patients (65 years) were treated with bid pre-prandial injections of BIAsp 30 during 
a 2-week run-in period and subsequently randomized to a 4-week treatment with 
either pre- or post-prandial bid BIAsp 30, followed by crossover to the other regi-
men for 4 weeks. Reproduced with permission from Warren ML, Conway MJ, Klaff 
LJ, Rosenstock J,   Allen E. Postprandial versus preprandial dosing of biphasic insulin 
aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract. 2004;66(1):23–29.23 
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